2025-11-24 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical (ISRG) based on the data provided.

**1) Return Rate Comparison & Alpha/Beta Analysis:**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **Return Rate Comparison:**
    *   ISRG Cumulative Return: 108.40%
    *   VOO (S&P 500) Cumulative Return: 94.64%
    *   Divergence: 13.8 (Relative Divergence: 37.7)
    *   **Analysis:** ISRG has significantly outperformed the S&P 500 over the tracked period. The divergence, while positive, is currently in the lower portion of its historical range, suggesting that the outperformance isn't at its peak relative to its past performance.

*   **Alpha/Beta Analysis:**

    | Year       | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
    |------------|-------|-------|--------|-------|--------|
    | 2015-2017  | 68.0% | 77.6% | 41.0%  | -0.1  | 43.6   |
    | 2016-2018  | 64.0% | 72.2% | 48.0%  | -0.0  | 57.2   |
    | 2017-2019  | 54.0% | 72.2% | 31.0%  | 0.2   | 70.6   |
    | 2018-2020  | -6.0% | 80.4% | -29.0% | 0.2   | 97.8   |
    | 2019-2021  | 29.0% | 80.4% | -18.0% | 0.5   | 128.8  |
    | 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2   | 95.1   |
    | 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7   | 120.9  |
    | 2022-2024  | 36.0% | 77.5% | 15.0%  | 1.7   | 187.1  |
    | 2023-2025  | 71.0% | 72.7% | 11.0%  | 0.8   | 201.3  |

    *   **CAGR (Compound Annual Growth Rate):** Volatile, with significant growth in earlier and more recent periods, and declines in others.
    *   **MDD (Maximum Drawdown):** Consistently high, indicating significant price volatility.
    *   **Alpha:** Generally positive in earlier periods, suggesting outperformance compared to its risk-adjusted benchmark. However, it's been negative in more recent periods.
    *   **Beta:** Low or slightly negative initially, but has increased significantly in recent years, suggesting ISRG's price movements are now more correlated with the overall market.
    *   **Cap (B):** Market capitalization has generally trended upwards, although not consistently.

**2) Recent Stock Price Fluctuations:**

*   Current Close: 561.61
*   Previous Close: 552.23, Change: 1.7
*   5-day SMA: 554.39
*   20-day SMA: 552.25
*   60-day SMA: 486.31

*   **Analysis:** The stock is trading above all its Simple Moving Averages (SMAs). The 5-day SMA is above the 20-day SMA, which is significantly above the 60-day SMA, indicating a strong upward trend in the short to medium term. The recent positive price movement (change: 1.7) further confirms this upward momentum.

**3) RSI, PPO, and Hybrid Signal:**

*   Market Risk Indicator (MRI): 0.8 (Medium Investment Recommended)
*   RSI: 58.35
*   PPO: -0.73
*   Hybrid Signal: cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   Recent (20 days) relative divergence change = 6.1 (+): 단기상승
*   Expected Return (%): 21.0

*   **Analysis:**
    *   The MRI of 0.8 suggests a "Medium Investment Recommended" rating.
    *   RSI of 58.35 indicates the stock is neither overbought nor oversold.
    *   PPO of -0.73 suggests the stock's short-term moving average is slightly below its long-term moving average, but the value is close to zero.
    *   The Hybrid Signal recommends a full investment with no cash, suggesting confidence in the stock's near-term performance, and indicating the monthly investment amount.
    *   The recent increase in relative divergence change (6.1) confirms the short-term uptrend.
    *   An expected return of 21% is highly attractive, suggesting potential for significant long-term gains exceeding the S&P 500's performance.

**4) Recent News & Significant Events:**

*   The news headlines are predominantly positive:
    *   Potential target price of $700 (Forbes).
    *   Positive earnings turnaround (Investor's Business Daily).
    *   Discussions about whether to buy, hold, or sell given recent gains (Yahoo Finance, Simply Wall St.).
    *   Fund adding to its ISRG position (Quiver Quantitative).
    *   Comparison to Medtronic as a potentially safer healthcare investment (The Motley Fool).

*   **Analysis:** Recent news indicates positive sentiment surrounding ISRG, driven by earnings and potential upside. The headlines highlight analyst optimism and institutional investment.

**4-2) Analyst Opinions:**

*   Consensus: Buy
*   Mean Rating: 2.00 (~Buy)
*   Opinions: 29
*   Target Price (avg/high/low): 592.96 / 700.00 / 378.00

*   **Analysis:** The analyst consensus is a "Buy" with an average target price of $592.96, suggesting further upside potential from the current price. The high target of $700 aligns with some of the news reports.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-10-22 | 1.98 | 2.51 B$  |
| 2025-07-23 | 1.84 | 2.44 B$  |
| 2025-04-23 | 1.95 | 2.25 B$  |
| 2024-10-18 | 1.59 | 2.04 B$  |
| 2025-10-22 | 1.59 | 2.04 B$  |

*   **Analysis:** Both EPS and revenue have generally increased over the past four quarters. This positive earnings trend is a strong indicator of the company's financial health and growth potential. Please note the duplicate entry of 2025-10-22 and 2024-10-18. I am assuming it is a typo and that the last line should say 2024-10-18.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $2.51B   | 66.36%        |
| 2025-06-30   | $2.44B   | 66.31%        |
| 2025-03-31   | $2.25B   | 64.69%        |
| 2024-12-31   | $2.41B   | 68.04%        |
| 2024-09-30   | $2.04B   | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-09-30   | $16.93B  | 4.16%   |
| 2025-06-30   | $17.85B  | 3.69%   |
| 2025-03-31   | $17.11B  | 4.08%   |
| 2024-12-31   | $16.43B  | 4.17%   |
| 2024-09-30   | $15.58B  | 3.63%   |

*   **Analysis:** Revenue has been increasing steadily, except for a dip in Q4 2024. The profit margin remains very high, reflecting ISRG's strong market position. Equity has grown consistently, and ROE (Return on Equity) has been fluctuating in a tight range, indicating consistent profitability relative to shareholder equity.

**7) Comprehensive Analysis (Summary):**

Intuitive Surgical (ISRG) appears to be a strong company with significant growth potential. Here's a summary of the key findings:

*   **Performance:** ISRG has outperformed the S&P 500 historically and is currently in a strong uptrend, supported by recent positive price action, favorable news, and analyst ratings.
*   **Financials:** Revenue, EPS, and profit margins are healthy and generally increasing.
*   **Sentiment:** Market sentiment is positive, with analyst consensus recommending a "Buy" and news highlighting the company's recent turnaround and growth prospects.
*   **Risks:** The high MDD and increasing Beta suggest that ISRG can be volatile and more correlated to the market. However, The Market Risk Indicator shows a medium investment.

**Overall Recommendation:** Based on the provided data, ISRG appears to be a promising investment, especially for investors seeking long-term growth and willing to tolerate some volatility. The analyst's opinion, Hybrid Signal, and news headlines further strengthen the argument for a positive outlook on ISRG.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.